NCT06386198 HEalth Advocate for Liver Transplantation: Improving Transition of Care for Adolescent Liver Transplant Recipients
| NCT ID | NCT06386198 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, San Francisco |
| Condition | Liver Transplant; Complications |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2024-03-03 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2024-03-03 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Health Advocate for Liver Transplant (HEAL-Tx) Transition of Care Pilot is a nonrandomized, open-label intervention pilot of a health advocate intervention aimed to assess feasibility and acceptability of integrating a Health Advocate onto the transplant team to help adolescents transition their care to adult transplant teams. Across studies, health advocate roles vary, and can include coordinating medical care treatment, facilitating financial assistance (e.g., taxi vouchers), and connecting patients to community resources, which can improve self-management, mitigate social risks, and lead to better communication between the healthcare system and the family. In this pilot, the investigators will adapt this intervention for adolescent/young adult liver transplant patients and measure acceptability and feasibility according to RE-AIM.
Eligibility Criteria
Inclusion Criteria: 1. Patient has received a liver transplant \>1 year ago 2. Study team has screened patient and discussed with the primary transplant practitioner that patient may benefit from the Health Advocate program. 3. Patient has an unmet social risk (e.g., food insecurity) or MLVI \>/= 2.0. 4. Patient will be transferred to adult transplant team in \<6 months. 5. Patient can read and write English or Spanish 6. Patient is between 18-25 years old and can provide informed consent. 7. Patient has a working phone and smart device capable of video and/or audio virtual visits via Zoom. Exclusion Criteria: * Patient has significant cognitive impairment. * Does not meet age criteria * Patient is a ward of the state. * Non-English, non-Spanish speakers. * Non-US residents.
Contact & Investigator
Sharad Wadhwani, MD, MPH
PRINCIPAL INVESTIGATOR
University of California, San Francisco
Frequently Asked Questions
Who can join the NCT06386198 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 25 Years, studying Liver Transplant; Complications. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06386198 currently recruiting?
Yes, NCT06386198 is actively recruiting participants. Contact the research team at sharad.wadhwani@ucsf.edu for enrollment information.
Where is the NCT06386198 trial being conducted?
This trial is being conducted at San Francisco, United States, Atlanta, United States.
Who is sponsoring the NCT06386198 clinical trial?
NCT06386198 is sponsored by University of California, San Francisco. The principal investigator is Sharad Wadhwani, MD, MPH at University of California, San Francisco. The trial plans to enroll 20 participants.